Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefaclor Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefaclor Anhydrous SCHEMBL49912 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL33540 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8626211 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8524989 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8943624 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL6155629 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL16072812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8478823 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8626208 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL27281884 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0038626-A1 | A process for electrolytic reduction of cephalosporin p-nitrobenzyl esters | ELI LILLY AND COMPANY (US) | 1981-10-28 | — | — | EP | claimed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | claimed |
| US-9163034-B2 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-20150005491-A1 | CRYSTALLINE (6R,7R)-7--3- [(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0] OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | BASILEA PHARMACEUTICA AG (CH) | 2015-01-01 | — | — | US | disclosed |
| US-8865697-B2 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| EP-2268648-B1 | Crystalline (6R,7R)-7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert- butoxycarbonyl-2-oxo-[1,3]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use | BASILEA PHARMACEUTICA AG (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-20110137026-A1 | Crystalline (6r,7r)-7--3- [(R)-1'-Tert-Butoxycarbonyl-2-Oxo-[1,3']Bipyrrolidinyl-(3e)-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0] Oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester; Its Manufacture and Use | BASILEA PHARMACEUTICA AG (CH) | 2011-06-09 | — | — | US | disclosed |
| EP-2268648-A1 | CRYSTALLINE (6R,7R)-7-{2-(5-AMINO-Ý1,2,4¨THIADIAZOL-3-YL)-2-Ý(Z)-TRITYLOXYIMINO¨-ACETYLAMINO}-3-Ý(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-Ý1,3'¨BIPYRROLIDINYL-(3E)-YLIDENEMETHYL¨-8-OXO-5-THIA-1-AZA-BICYCLOÝ4.2.0¨OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | Basilea Pharmaceutica AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009127623-A1 | CRYSTALLINE (6R,7R)-7-{2-(5-AMINO-[1,2,4]THIADIAZOL-3-YL)-2-[(Z)-TRITYLOXYIMINO]-ACETYLAMINO}-3-[(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | BASILEA PHARMACEUTICA AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| EP-0730035-A1 | Improved enzymatic process for producing penicillins and cephalosporins | ACS DOBFAR S.p.A. (IT) | 1996-09-04 | — | — | EP | disclosed |
| US-5532353-A | Process for the preparation of halogenated β-lactam compounds | BIOCHIMICA OPOS SPA (IT) | 1996-07-02 | — | — | US | disclosed |
| US-4338436-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4319028-A | 7-(2-(Substituted benzoyl)amino)acetamido)cephalosporins | ELI LILLY AND COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| EP-0038626-A1 | A process for electrolytic reduction of cephalosporin p-nitrobenzyl esters | ELI LILLY AND COMPANY (US) | 1981-10-28 | — | — | EP | disclosed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4271305-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| US-4237279-A | Crystalline 3-hydroxycephalosporin solvates | ELI LILLY AND COMPANY (US) | 1980-12-02 | — | — | US | disclosed |
| US-4226986-A | 7-ACYLAMINO-3-HYDROXY-3-CEPHEM COMPOUND, TRIARYL PHOSPHITE DIHALIDE | ELI LILLY AND COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| EP-0014565-A1 | 3-Hydroxycephalosporin solvates and process for their production | ELI LILLY AND COMPANY (US) | 1980-08-20 | — | — | EP | disclosed |
| US-4091214-A | ALPHA-HYDROXY CARBOXYLIC ACID | ELI LILLY AND COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005491-A1 | CRYSTALLINE (6R,7R)-7--3- [(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0] OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE | MED1, MED16, CYP2D6 | ALDH1A1 669/4885HSD17B10 2018/4885MAPT 2798/4885 |
| US-20110137026-A1 | Crystalline (6r,7r)-7--3- [(R)-1'-Tert-Butoxycarbonyl-2-Oxo-[1,3']Bipyrrolidinyl-(3e)-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0] Oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester; Its Manufacture and Use | MED1, MED16, CYP2D6 | ALDH1A1 669/4885HSD17B10 2018/4885MAPT 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.